Siegfried Holding AG
SIX:SFZN

Watchlist Manager
Siegfried Holding AG Logo
Siegfried Holding AG
SIX:SFZN
Watchlist
Price: 1 104 CHF -1.43%
Market Cap: 4.7B CHF
Have any thoughts about
Siegfried Holding AG?
Write Note

Siegfried Holding AG
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Siegfried Holding AG
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Siegfried Holding AG
SIX:SFZN
Total Equity
CHf906.7m
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Total Equity
CHf1.3B
CAGR 3-Years
39%
CAGR 5-Years
26%
CAGR 10-Years
15%
Lonza Group AG
SIX:LONN
Total Equity
CHf9.5B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
16%
Tecan Group AG
SIX:TECN
Total Equity
CHf1.4B
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Total Equity
€381.2m
CAGR 3-Years
29%
CAGR 5-Years
21%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Total Equity
CHf169.2m
CAGR 3-Years
60%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

Siegfried Holding AG
Glance View

Market Cap
4.7B CHF
Industry
Life Sciences Tools & Services

Siegfried Holding AG engages in the development and manufacture of active pharmaceutical ingredients for pharmaceutical clients with research and development programs, related intermediates, and controlled substances. The company is headquartered in Zofingen, Aargau and currently employs 3,432 full-time employees. The firm produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and steriles. The firm's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The firm operates production facilities in Switzerland, Germany, France, Malta, the United States and China.

SFZN Intrinsic Value
1 201.55 CHF
Undervaluation 8%
Intrinsic Value
Price

See Also

What is Siegfried Holding AG's Total Equity?
Total Equity
906.7m CHF

Based on the financial report for Jun 30, 2024, Siegfried Holding AG's Total Equity amounts to 906.7m CHF.

What is Siegfried Holding AG's Total Equity growth rate?
Total Equity CAGR 5Y
5%

Over the last year, the Total Equity growth was 13%. The average annual Total Equity growth rates for Siegfried Holding AG have been 5% over the past three years , 5% over the past five years .

Back to Top